Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239268 | 1.00 | BTK (0.50) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL31402079 | 1.00 | BTK (0.50) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL15294478 | 1.00 | BTK (0.50) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL570579 | 0.85 | GAA (0.49) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL509300 | 0.82 | BTK (0.48) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL12528056 | 0.82 | BTK (0.48) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL15540916 | 0.81 | BTK (0.54) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL21549474 | 0.81 | BTK (0.54) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL13961431 | 0.79 | BTK (0.52) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL18928233 | 0.79 | BTK (0.52) | BTKCA1CA2GAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654748-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9351965-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351965-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-10-03 | — | — | US | disclosed |
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-10-03 | — | — | US | disclosed |
| WO-2012087772-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | BTK 349/4885CA1 4121/4885CA2 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.